Healthcare >> CEO Interviews >> November 15, 2010
Dr. Phillip P. Chan, M.D., Ph.D., is the CEO and President of CytoSorbents Corporation (CTSO). Prior to CytoSorbents, Dr. Chan led health care and life science investments as Partner for the $80M NJTC Venture Fund. Dr. Chan also co-founded Andrew Technologies, a venture-backed medical device company commercializing its HydraSolve Lipoplasty system. Dr. Chan is a board-certified internal medicine physician and completed his residency at Harvard Medical School at the Beth Israel Deaconess Medical Center. Dr. Chan received his M.D./Ph.D. from Yale University School of Medicine, and his B.S. in cell and molecular biology from Cornell University. Profile
TWST: Please start with a general overview and a history of the company.
Dr. Chan: CytoSorbents (CTSO), formerly known as MedaSorb Technologies Corporation, is a critical-care focused medical device
